Safety Study of RMJH-111b to Treat Essential Hypertension

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (49 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: first dosedlplacebostudy drugof study
  Phrases that lowered it: screeningevaluatethe effecteffect ofessential hypertension
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 53.2% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 4.0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 3383 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension NCT03971929 · started 2019 · scored riskier than 23% of active trials completed
• A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009) NCT01370655 · started 2011 · scored riskier than 11% of active trials completed
• Effect of Metamizole (Dipyrone) on Renal Function in Salt-depleted Healthy Subjects NCT01995006 · started 2014 · scored riskier than 2% of active trials completed
• A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers NCT01590446 · started 2012 · scored riskier than 3% of active trials completed
• A Single Rising Dose Study of MK-8150 (MK-8150-001) NCT01590810 · started 2012 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.